XOMA (US) LLC (XOMA) Highlights Recent Achievements and Reports Financial Results for First Quarter 2013
5/9/2013 10:17:11 AM
More...
|
XOMA (US) LLC (XOMA) to Present at Credit Suisse First Boston 2013 Antibody Day
5/7/2013 9:59:45 AM
More...
|
XOMA (US) LLC (XOMA) Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris
1/7/2013 9:39:28 AM
More...
|
XOMA (US) LLC (XOMA) Selects Non-Infectious Anterior Scleritis as Next Indication in Gevokizumab Proof-of-Concept Program
1/2/2013 9:10:56 AM
More...
|
XOMA (US) LLC (XOMA) Appoints Joseph M. Limber to Its Board of Directors
12/13/2012 9:55:47 AM
More...
|
XOMA (US) LLC (XOMA) to Present at Credit Suisse Healthcare Conference
11/9/2012 10:19:33 AM
More...
|
XOMA (US) LLC (XOMA) Reports Financial Results for Third Quarter 2012 and Highlights Recent Achievements
11/8/2012 9:50:51 AM
More...
|
XOMA (US) LLC (XOMA) to Announce Third Quarter 2012 Financial Results and Host Webcast on November 7
11/1/2012 7:26:44 AM
More...
|
XOMA (US) LLC (XOMA) Announces Pricing of $40.0 Million Public Offering of Common Stock
10/24/2012 8:30:41 AM
More...
|
XOMA (US) LLC (XOMA) Initiates Safety and Efficacy Study of Gevokizumab in Patients With Non-Infectious Uveitis Currently Controlled by Systemic Treatment
10/4/2012 10:07:13 AM
More...
|
|